KRAS G12S
Clinical trials for KRAS G12S explained in plain language.
Never miss a new study
Get alerted when new KRAS G12S trials appear
Sign up with your email to follow new studies for KRAS G12S, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy option for pancreatic cancer patients with no other choices
Disease control AVAILABLEThis program provides early access to an experimental immunotherapy called ELI-002 7P for people with a specific type of pancreatic cancer (KRAS/NRAS-mutated) who have had their tumor removed but are at high risk of the cancer coming back. It is for patients who have no other tre…
Matched conditions: KRAS G12S
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…
Matched conditions: KRAS G12S
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 20, 2026 11:58 UTC